California-based biotechnology company Alector plans to sell its common stock to the public.

The company will land a total of up to $150 million in the listing.

With the initial public offering, Alector will advance its pipeline of drug treatment candidates for dementia and Alzheimer's disease conditions.

The company, which has raised a funding total of $194.5 million in over five rounds, filed with Securities and Exchange Commission.